12:00 AM
Feb 18, 2013
 |  BioCentury  |  Finance

Expanding network

e-Therapeutics asking shareholders to double-down on MDD, cancer compounds
Expanding network

When e-Therapeutics plc (LSE:ETX) closes its £40 million ($63 million) placing, the money will nearly match the company's £42.5 million market cap at the time the deal was announced and surpass the total amount it has previously raised from the public markets.

The influx of cash will allow the network pharmacology company to increase its focus on discovering NCEs for cancer and neurodegeneration while getting its legacy repurposing programs to clinical proof of concept.

The placing of 125 million shares...

Read the full 390 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >